Literature DB >> 8093345

Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.

L E Robertson1, S Chubb, R E Meyn, M Story, R Ford, W N Hittelman, W Plunkett.   

Abstract

2-Chloro-2'-deoxyadenosine (CldAdo) and 9-beta-D-arabinosyl-2-fluoroadenine (F-ara-A) have shown marked activity in the treatment of indolent lymphoid malignancies. Based on the susceptibility of various lymphocyte populations to apoptosis, we investigated whether CldAdo or F-ara-A would induce this process in lymphocytes from patients with chronic lymphocytic leukemia (CLL). In vitro exposure of leukemic lymphocytes to CldAdo or F-ara-A for 24 to 72 hours elicited features of apoptosis visible by light and electron microscopy. Analysis of DNA integrity showed DNA cleavage into nucleosomal-sized multimers. Using a quantitative assay, drug-induced DNA fragmentation was both time and dose dependent. Inhibition of active macromolecular synthesis did not prevent drug-induced fragmentation; however, both drug-induced and spontaneous DNA fragmentation were prevented by intracellular calcium chelation. In vitro culture with phorbol ester generally decreased drug-induced DNA cleavage. After prolonged incubation, CLL cells exhibited spontaneous cleavage; albeit, at significantly lower rates than drug-treated cells. Heterogeneity was observed for spontaneous and drug-induced DNA fragmentation and was significantly lower in B-leukemic cells obtained from patients with high-risk and refractory disease. We conclude that CldAdo and F-ara-A are potent inducers of apoptotic death in CLL and that this feature correlates with the disease status.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093345

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.

Authors:  Yusuf Baran; Jacek Bielawski; Ufuk Gunduz; Besim Ogretmen
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-11       Impact factor: 4.553

Review 2.  Apoptosis in B-chronic lymphocytic leukaemia.

Authors:  L M Osorio; M Aguilar-Santelises
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

Review 3.  Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.

Authors:  M Merup
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

4.  Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia.

Authors:  Kazutaka Takagi; Yasukazu Kawai; Takahiro Yamauchi; Hiromichi Iwasaki; Takanori Ueda
Journal:  Int J Hematol       Date:  2011-09-23       Impact factor: 2.490

Review 5.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

6.  Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.

Authors:  Tieran Han; Marilyn Fernandez; Ting-Chao Chou; Ram P Agarwal
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 7.  The optimal management of hairy cell leukaemia.

Authors:  R Gollard; T C Lee; L D Piro; A Saven
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

8.  Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists.

Authors:  Y Kohno; Y Sei; M Koshiba; H O Kim; K A Jacobson
Journal:  Biochem Biophys Res Commun       Date:  1996-02-27       Impact factor: 3.575

9.  Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

Authors:  Francesca Ricci; Alessandra Tedeschi; Enrica Morra; Marco Montillo
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

10.  Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.

Authors:  J E Rubnitz; K R Crews; S Pounds; S Yang; D Campana; V V Gandhi; S C Raimondi; J R Downing; B I Razzouk; C-H Pui; R C Ribeiro
Journal:  Leukemia       Date:  2009-02-26       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.